Strain Name:

B6.Cg-Tg(Gfap-TK)7.1Mvs/J

Stock Number:

005698

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Other products are available, see Purchasing Information for Cryopreserved Embryos

Transgene-derived HSV-TK in these mice is present exclusively in cells expressing endogenous Gfap. This co-expression occurs in brain astrocytes and adult neural stem cells, enteric glia, hepatic stellate cells, and unknown cells in heart, lung, kidney, adrenal, and spleen. This mutant can be used in studies of adult neurogenesis, nervous system injury/repair mechanisms, and inflammatory bowel disease.

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names B6.Cg-Tg(Gfap-Tk)7.1Mvs/J    (Changed: 05-SEP-11 )
Type Congenic; Mutant Strain; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Specieslaboratory mouse
GenerationN12+N1pN1p
Generation Definitions
 
Donating Investigator Michael V Sofroniew,   University of California Los Angeles

Description
Mice hemizygous for the transgenic insert are viable, normal in size, and do not display any behavioral abnormalities. Transgenic males are infertile. Proliferating cells that express the herpes simplex virus thymidine kinase (HSV-TK) transgene will metabolize ganciclovir (GCV) to toxic nucleotide analogues and undergo cell death. Transgene-derived HSV-TK is present exclusively in cells expressing endogenous Gfap. This co-expression occurs in brain astrocytes and adult neural stem cells, enteric glia, hepatic stellate cells, and unknown cells in heart, lung, kidney, adrenal, and spleen. Chronic GCV treatment for 21 days depletes GFAP-positive adult neural stem cells from forebrain proliferative zones. GCV treatment eliminated growth of primary multipotent neurospheres cultured from the germinal zones of postnatal and adult, but not early embryonic, transgenic mice. Notably, the same treatment prevented growth of secondary multipotent neurospheres from all three developmental stages. Stab or spinal cord injury with high dose GCV treatment for 7 days induces reactive astroctye cell death leading to altered leukocyte trafficking and impaired injury healing. High dose GCV treatment for 14 days ablates GFAP-positive glia from the jejunum and ileum leading to fulminant and fatal jejuno-ileitis. This mutant can be used in studies of adult neurogenesis, nervous system injury/repair mechanisms, and inflammatory bowel disease.

Development
A herpes simplex virus thymidine kinase (HSV-TK) construct was inserted into the first exon of a mouse glial fibrillary acidic protein (GFAP) promoter cassette (clone 445). This cassette contains all the introns, promoter regulatory elements, exons, and 2.5 kb of 5' and 2 kb of 3' flanking regions of Gfap. Transgenic Gfap expression is prevented because a small segment of exon 1 has been removed in the clone. The Gfap-HSV-Tk fusion gene was injected into the male pronucleus of fertilized eggs from superovulated female C57BL/10 x CBA mated with CFLP outbred Swiss albino males. Two-cell stage eggs were implanted into pseudopregnant foster mothers. Founder line 7.1 was obtained and backcrossed to C57BL/6 mice by the donating investigator (see SNP note below) for more than 12 generations.

A 32 SNP (single nucleotide polymorphism) panel analysis, with 27 markers covering all 19 chromosomes and the X chromosome, as well as 5 markers that distinguish between the C57BL/6J and C57BL/6N substrains, was performed on the rederived living colony at The Jackson Laboratory Repository. While the 27 markers throughout the genome suggested a C57BL/6 genetic background, at least 2 of 5 markers that determine C57BL/6J from C57BL/6N were found to be segregating. These data suggest the mice sent to The Jackson Laboratory Repository were on a mixed C57BL/6J ; C57BL/6N genetic background.

Control Information

  Control
   Noncarrier
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Tg(Gfap-TK)7.1Mvs allele
017523   129S6.Cg-Tg(Gfap-TK)7.1Mvs/RhnJ
View Strains carrying   Tg(Gfap-TK)7.1Mvs     (1 strain)

View Strains carrying other alleles of Gfap     (7 strains)

View Strains carrying other alleles of HSV-TK     (4 strains)

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Tg(Gfap-TK)7.1Mvs/0

        involves: C57BL/10 * CBA * CFLP
  • mortality/aging
  • decreased sensitivity to xenobiotic induced morbidity/mortality
    • untreated nontransgenic mice show no effects beyond reduced activity and ruffled fur after 28 days of 100 mg/kg/day ganciclovir (GCV) treatment   (MGI Ref ID J:104241)
    • when treated with GCV up to 7 days, mice survive for at least 35 days; when treated for 14 days then stopped, mice become terminally ill and death occurs between 13 and 19 days (100% mortality) with or without a brain injury   (MGI Ref ID J:104241)
  • homeostasis/metabolism phenotype
  • abnormal enzyme/coenzyme activity
    • in GCV-treated transgenic mice, a substantial increase in myeloperoxidase (MPO) activity, a quantitative measure of inflammatory response, in ileum not duodenum or colon compared to nontransgenic mice   (MGI Ref ID J:104241)
  • decreased sensitivity to xenobiotic induced morbidity/mortality
    • untreated nontransgenic mice show no effects beyond reduced activity and ruffled fur after 28 days of 100 mg/kg/day ganciclovir (GCV) treatment   (MGI Ref ID J:104241)
    • when treated with GCV up to 7 days, mice survive for at least 35 days; when treated for 14 days then stopped, mice become terminally ill and death occurs between 13 and 19 days (100% mortality) with or without a brain injury   (MGI Ref ID J:104241)
  • edema
    • in some affected mice, interstitial edema separating the epithelium from the lamina propria is observed   (MGI Ref ID J:104241)
  • impaired wound healing
    • GCV-treated transgenic mice show reactive astrocyte death and impaired glial scar formation after stab injury to the brain   (MGI Ref ID J:104241)
  • increased blood urea nitrogen level
    • transgenic mice receiving GCV for 14 days have mildly (30%) elevated serum urea levels   (MGI Ref ID J:104241)
    • moribund treated transgenics have 3-fold elevated serum urea levels compared to untreated controls   (MGI Ref ID J:104241)
  • increased susceptibility to neuronal excitotoxicity
    • many CA1 neurons in GCV-treated mice show morphological signs of excitotoxic cell death, compared to control mice   (MGI Ref ID J:113202)
  • digestive/alimentary phenotype
  • abnormal digestive system physiology
    • transgenic mice receiving 100 mg/kg/day GCV for 14 show growth of gram-negative organisms (>300 colonies per spleen or ml of blood or peritoneal fluid) while controls have none   (MGI Ref ID J:104241)
    • GCV-treated mice have a 10- to 100-fold increase in numbers of aerobic and anaerobic bacterial colonies per gram tissue in ileum compared to untreated or GVC-treated nontransgenic mice   (MGI Ref ID J:104241)
    • abnormal feces composition
      • the fecal contents of transgenic mice given GCV for >11 days are black, melanic and test positive for occult blood   (MGI Ref ID J:104241)
    • gastrointestinal hemorrhage
      • ileum and jejunum of transgenics treated with GCV for >11 days exhibit hemorrhage   (MGI Ref ID J:104241)
    • small intestinal inflammation
      • ileum and jejunum of transgenics treated with GCV for >11 days show severe inflammation   (MGI Ref ID J:104241)
      • progression changes in inflammation lead to increased transmigration of polymorphonuclear leukocytes leading to granulocytic inflammatory infiltrate of lamina propria   (MGI Ref ID J:104241)
  • abnormal intestinal mucosa morphology
    • surface exhibits areas of superficial erosion covered with inflammatory exudates and cellular debris   (MGI Ref ID J:104241)
    • villus atrophy is minor, but villi exhibit patchy lesions ranging from mild epithelial changes and nonspecific granulocytic infiltrate to marked hemorrhagic necrosis   (MGI Ref ID J:104241)
    • villus tips show flattening, vacuolization and loss of polarity of surface epithelium; loss of brush border and pronounced dilation of capillaries with erythrostasis with chronic GCV treatment   (MGI Ref ID J:104241)
    • villi in severely affected regions can show disintegration of the tips resulting in a hemorrhagic and inflammatory exudates into the lumen of intestine   (MGI Ref ID J:104241)
    • lamina propria becomes inflamed in affected mice; fibrosis of, and hemorrhage into lamina propria can be seen in severe cases   (MGI Ref ID J:104241)
    • surface exhibits areas of superficial erosion covered with inflammatory exudates and cellular debris in trangenics after chronic GCV treatment   (MGI Ref ID J:104241)
    • progressive changes include increased sloughing of epithelial cells   (MGI Ref ID J:104241)
    • abnormal crypts of Lieberkuhn morphology
      • a significant 50% increase in crypt depth is seen with chronic GCV treatment   (MGI Ref ID J:104241)
      • progressive changes include crypt hyperplasia   (MGI Ref ID J:104241)
    • abnormal intestinal goblet cell morphology
      • some treated animals with severe pathology show loss of goblet cells   (MGI Ref ID J:104241)
  • abnormal small intestine morphology
    • ileum and jejunum of transgenics treated with GCV (100 mg/kg/day) for >11 days exhibit moderate distention   (MGI Ref ID J:104241)
    • small intestine shows patchy skip lesions ranging from small inflammatory foci to large apthoid and linear ulcers exhibiting gangrenous necrosis in extreme cases   (MGI Ref ID J:104241)
    • inflammation and hemorrhagic necrosis of the submucosa and muscularis externa can be seen in severely affected regions   (MGI Ref ID J:104241)
    • abnormal ileum morphology
      • ileum of affected mice is generally more severely affected than jejunum; lesions occur with equal frequency within the proximal, central or distal portions   (MGI Ref ID J:104241)
      • some areas of severely affected ileal mucosa is associated with necrosis of the underlying smooth muscle and transmural perforation   (MGI Ref ID J:104241)
      • the smooth muscle wall of the ileum shows an obvious 100% thickening   (MGI Ref ID J:104241)
      • distended ileum
        • ileum of transgenics treated with GCV (100 mg/kg/day) for >11 days exhibits moderate distention   (MGI Ref ID J:104241)
    • abnormal jejunum morphology
      • jejunum of GCV-treated mice displays similar pathology to the ileum, but usually with less severity   (MGI Ref ID J:104241)
      • distended jejunum
        • jejunum of transgenics treated with GCV (100 mg/kg/day) for >11 days exhibits moderate distention   (MGI Ref ID J:104241)
  • nervous system phenotype
  • *normal* nervous system phenotype
    • uninjured transgenic mice receiving 100 mg/kg/day GCV for 14-17 days show no evidence of neuronal damage or astrocyte loss throughout the CNS   (MGI Ref ID J:104241)
    • abnormal astrocyte physiology
      • transgenic astrocytes are sensitive to prolonged exposure to subcutaneous GCV, resulting in cell death   (MGI Ref ID J:104241)
      • after a stab injury to brain and continuous GCV delivery in vivo for 7 or 14 days, transgenic mice show few astrocytes adjacent to wound margin and astrocytes in adjacent tissue look fragmented and abnormal (early stages of cell death)   (MGI Ref ID J:104241)
    • abnormal blood-brain barrier function
      • in treated control mice and untreated transgenic mice, blood-brain barrier (BBB) is repaired and resealed by 14 days after injury where stab injury damage occurred; GCV-treated transgenics still show BBB disruption by IgG entry into CNS parenchyma at 35 days after injury   (MGI Ref ID J:113202)
    • abnormal enteric nervous system morphology
      • after 14 days of GCV treatment, transgenic mice show pronounced loss of glial (GFAP +ve) cells from myenteric plexus in jejunum and ileum; widespread loss from submucosal regions and lamina propria of villi throughout jejunum and ileum is seen   (MGI Ref ID J:104241)
      • abnormal enteric neuron morphology
        • the dense network of glial cell processes that envelop the myenteric neurons in controls is markedly depleted in transgenic mice receiving GCV for 14 days   (MGI Ref ID J:104241)
        • in areas where many glial cells are absent, neuronal atrophy and loss can be observed   (MGI Ref ID J:104241)
        • in transgenics after GCV treatment there are 31% fewer myenteric neurons and remaining neurons have a 27% smaller mean cross-sectional area   (MGI Ref ID J:104241)
    • abnormal glial cell morphology
      • remaining enteric glia after 14 days of GCV treatment are abnormal   (MGI Ref ID J:104241)
      • abnormal CNS glial cell morphology
        • after a stabbing injury to the forebrain, transgenic mice treated with ganciclovir (GCV) subcutaneously for 7 or 14 days show a reduction in astrocytes immediately adjacent to wound and for several hundred microns away, most strikingly the thalamus   (MGI Ref ID J:113202)
        • astrocytosis
          • death of astrocytes immediately next to the wound triggers extensive astrocytosis in outwardly adjacent cells compared to controls   (MGI Ref ID J:113202)
    • abnormal innervation
      • GCV-treated mutants show a dense network of many finely branched, randomly-oriented fibers with a sprouting appearance comfined to the wound margin and not extending into unaffected regions while control mice show very few fibers in scar-forming region   (MGI Ref ID J:113202)
    • abnormal neuron differentiation
      • in transgenic mice treated daily with low-dose ganciclovir (GCV), number of dividing cells decreases substantially in subependymal zone (SEZ) to 18.6% of controls and in subgranular zone (SGZ) to 29.6% of control   (MGI Ref ID J:94543)
      • transgenic mice treated chronically (14 days) with low-dose GCV have almost no newly generated neurons in SEZ, SGZ, or rostral migratory stream (RMS); in olfactory bulb 0% of neurons are NeuN-positive and in dentate gyrus only 1.8% are positive compared to controls (>98% reduction in neurogenesis)   (MGI Ref ID J:94543)
    • brain inflammation
      • in GCV-treated mutants, at 7 days after stab injury, there is marked interstitial edema within 400 microns of wound with numerous phagocytic and inflammatory cells and substantial neuronal degeneration   (MGI Ref ID J:113202)
      • blood vessels are dilated, a 25-fold greater density of leukocytes are present and persist for 14 days, and extravasated leukocytes (monocytes, macrophages, neutrophils, and lymphocytes) are common up to 2 mm from wound   (MGI Ref ID J:113202)
      • many microglia are seen adjacent to wound at 7 or 14 days and at 35 days, numerous leukocytes are still observed, while non-transgenic GCV-treated and transgenic untreated show little edema, a low density of leukocytes scattered around wound, and extravasated monocytes are rarely found in parenchyma at >1 mm from wound margin   (MGI Ref ID J:113202)
    • increased susceptibility to neuronal excitotoxicity
      • many CA1 neurons in GCV-treated mice show morphological signs of excitotoxic cell death, compared to control mice   (MGI Ref ID J:113202)
    • loss of hippocampal neurons
      • GCV-treated mice by 21 or 35 days after stab injury show few surviving pyramidal neurons within 1500 microns of wound and extensive tissue collapse; in control mice, region with no neurons extends <100 microns from the wound   (MGI Ref ID J:113202)
      • loss of neurons is seen in all brain tissue around the stab injury in GCV-treated transgenics   (MGI Ref ID J:113202)
    • neuron degeneration
      • loss of enteric glia results in a patchy, moderate degeneration of neurons intrinsic to the ileal myenteric plexus   (MGI Ref ID J:104241)
      • marked degeneration in the wound region is observed 7 days after injury in GCV-treated transgenics   (MGI Ref ID J:113202)
  • hematopoietic system phenotype
  • anemia
    • moribund treated transgenics display severe anemia   (MGI Ref ID J:104241)
  • decreased erythrocyte cell number
    • transgenic mice receiving 100 mg/kg/day GCV for 14 days have red blood cell counts reduced by 60%   (MGI Ref ID J:104241)
  • increased neutrophil cell number
    • transgenic mice receiving 100 mg/kg/day GCV for 14 days show 20-fold increase in neutrophils   (MGI Ref ID J:104241)
    • moribund treated transgenics have a high level of neutrophils relative to the number of red blood cells   (MGI Ref ID J:104241)
  • increased nucleated erythrocyte cell number
    • transgenic mice receiving GCV for 14 days show a 10-fold increase in nucleated red blood cells   (MGI Ref ID J:104241)
    • moribund treated transgenics have high levels of nucleated red blood cells   (MGI Ref ID J:104241)
  • immune system phenotype
  • abnormal inflammatory response
    • transgenic mice given 100 mg/kg/day GCV for 7 days show small patches of focal inflammation in the GI tract   (MGI Ref ID J:104241)
    • brain inflammation
      • in GCV-treated mutants, at 7 days after stab injury, there is marked interstitial edema within 400 microns of wound with numerous phagocytic and inflammatory cells and substantial neuronal degeneration   (MGI Ref ID J:113202)
      • blood vessels are dilated, a 25-fold greater density of leukocytes are present and persist for 14 days, and extravasated leukocytes (monocytes, macrophages, neutrophils, and lymphocytes) are common up to 2 mm from wound   (MGI Ref ID J:113202)
      • many microglia are seen adjacent to wound at 7 or 14 days and at 35 days, numerous leukocytes are still observed, while non-transgenic GCV-treated and transgenic untreated show little edema, a low density of leukocytes scattered around wound, and extravasated monocytes are rarely found in parenchyma at >1 mm from wound margin   (MGI Ref ID J:113202)
    • small intestinal inflammation
      • ileum and jejunum of transgenics treated with GCV for >11 days show severe inflammation   (MGI Ref ID J:104241)
      • progression changes in inflammation lead to increased transmigration of polymorphonuclear leukocytes leading to granulocytic inflammatory infiltrate of lamina propria   (MGI Ref ID J:104241)
  • increased neutrophil cell number
    • transgenic mice receiving 100 mg/kg/day GCV for 14 days show 20-fold increase in neutrophils   (MGI Ref ID J:104241)
    • moribund treated transgenics have a high level of neutrophils relative to the number of red blood cells   (MGI Ref ID J:104241)
  • endocrine/exocrine gland phenotype
  • abnormal crypts of Lieberkuhn morphology
    • a significant 50% increase in crypt depth is seen with chronic GCV treatment   (MGI Ref ID J:104241)
    • progressive changes include crypt hyperplasia   (MGI Ref ID J:104241)
  • cellular phenotype
  • abnormal cell death
    • in enriched subconfluent astrocyte cultures from neonatal mice, exposure to GCV for 7 days or more caused a 75% loss of astrocytes (GFAP +ve cells) with an increase in GFAP -ve cells compared to nontransgenic cultures   (MGI Ref ID J:104241)
    • increased susceptibility to neuronal excitotoxicity
      • many CA1 neurons in GCV-treated mice show morphological signs of excitotoxic cell death, compared to control mice   (MGI Ref ID J:113202)
  • abnormal cell proliferation
    • non-transgenic animals with or without GCV treatment show many proliferating astrocytes in narrow zone adjacent to stab wound associated with compact glial scar formation, but in GCV-treated mutants, essentially all proliferating astrocytes are ablated   (MGI Ref ID J:113202)
  • abnormal neuron differentiation
    • in transgenic mice treated daily with low-dose ganciclovir (GCV), number of dividing cells decreases substantially in subependymal zone (SEZ) to 18.6% of controls and in subgranular zone (SGZ) to 29.6% of control   (MGI Ref ID J:94543)
    • transgenic mice treated chronically (14 days) with low-dose GCV have almost no newly generated neurons in SEZ, SGZ, or rostral migratory stream (RMS); in olfactory bulb 0% of neurons are NeuN-positive and in dentate gyrus only 1.8% are positive compared to controls (>98% reduction in neurogenesis)   (MGI Ref ID J:94543)
  • cardiovascular system phenotype
  • abnormal blood-brain barrier function
    • in treated control mice and untreated transgenic mice, blood-brain barrier (BBB) is repaired and resealed by 14 days after injury where stab injury damage occurred; GCV-treated transgenics still show BBB disruption by IgG entry into CNS parenchyma at 35 days after injury   (MGI Ref ID J:113202)
  • gastrointestinal hemorrhage
    • ileum and jejunum of transgenics treated with GCV for >11 days exhibit hemorrhage   (MGI Ref ID J:104241)
  • reproductive system phenotype
  • male infertility
    • male transgenic mice are sterile   (MGI Ref ID J:104241)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Immunology, Inflammation and Autoimmunity Research
Immunodeficiency
      Inflammatory bowel disease
Inflammation
      Inflammatory bowel disease

Internal/Organ Research
Gastrointestinal Defects
Wound Healing
      delayed/impaired

Research Tools
Genetics Research
      Tissue/Cell Markers
      Tissue/Cell Markers: astrocytes
      Tissue/Cell Markers: astrocytes, neurons
      Tissue/Cell Markers: glial cells
Neurobiology Research

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(Gfap-TK)7.1Mvs
Allele Name transgene insertion 7.1, Michael V Sofroniew
Allele Type Transgenic (Inserted expressed sequence)
Common Name(s) GFAP-TK; Gfap-HSV-Tk;
Mutation Made By Michael Sofroniew,   University of California Los Angeles
Strain of Origin(C57BL/10 x CBA)F1 X CFLP
Expressed Gene HSV-TK, herpes simplex virus thymidine kinase,
Promoter Gfap, glial fibrillary acidic protein, mouse, laboratory
General Note Line 7.1, estimated to carry >50 copies of the transgene, was selected from three original lines (the others unnamed) for further analysis because mice of this line exhibited the greatest HSV thymidine kinase expression in the brain.

Ganciclovir is metabolized to toxic nucleotide analogs in cells expressing HSV-TK. Subcutaneous or intraperitoneal administration of ganciclovir (GCV) or elaidic acid ganciclovir (eGCV) to transgenic mice results in specific ablation of proliferating cells that express GFAP.

Molecular Note The Herpes simplex virus thymidine kinase gene, including the polyadenylation signal, was ligated into the first exon of a mouse glial fibrillary acidic protein promoter cassette that contains all the exons, introns and promoter regulatory elements and includes 2.5 kb of 5' and 2 kb of 3' flanking genomic DNA. The GFAP protein is not expressed from the transgene because a small segment of exon one has been deleted. RT-PCR analysis showed co-expression of HSV-Tk and of Gfap mRNA (fromthe endogenous gene) in heart, lung, liver, spleen, adrenal, kidney and GI tract, as well as in brain and trigeminal ganglion; in neural tissues the co-expressing cells have the appearance of astroglia. [MGI Ref ID J:104241]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Tg(Gfap-Tk)7.1Mvs,

MELT


Tg(Gfap-Tk)7.1Mvs, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Bush TG; Savidge TC; Freeman TC; Cox HJ; Campbell EA; Mucke L; Johnson MH; Sofroniew MV. 1998. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 93(2):189-201. [PubMed: 9568712]  [MGI Ref ID J:104241]

Additional References

Tg(Gfap-TK)7.1Mvs related

Bush TG; Puvanachandra N; Horner CH; Polito A; Ostenfeld T; Svendsen CN; Mucke L; Johnson MH; Sofroniew MV. 1999. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23(2):297-308. [PubMed: 10399936]  [MGI Ref ID J:113202]

Falsig J; Julius C; Margalith I; Schwarz P; Heppner FL; Aguzzi A. 2008. A versatile prion replication assay in organotypic brain slices. Nat Neurosci 11(1):109-17. [PubMed: 18066056]  [MGI Ref ID J:130808]

Faulkner JR; Herrmann JE; Woo MJ; Tansey KE; Doan NB; Sofroniew MV. 2004. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 24(9):2143-55. [PubMed: 14999065]  [MGI Ref ID J:113201]

Garcia AD; Doan NB; Imura T; Bush TG; Sofroniew MV. 2004. GFAP-expressing progenitors are the principal source of constitutive neurogenesis in adult mouse forebrain. Nat Neurosci 7(11):1233-41. [PubMed: 15494728]  [MGI Ref ID J:94543]

Imura T; Kornblum HI; Sofroniew MV. 2003. The predominant neural stem cell isolated from postnatal and adult forebrain but not early embryonic forebrain expresses GFAP. J Neurosci 23(7):2824-32. [PubMed: 12684469]  [MGI Ref ID J:113203]

Imura T; Nakano I; Kornblum HI; Sofroniew MV. 2006. Phenotypic and functional heterogeneity of GFAP-expressing cells in vitro: differential expression of LeX/CD15 by GFAP-expressing multipotent neural stem cells and non-neurogenic astrocytes. Glia 53(3):277-93. [PubMed: 16267834]  [MGI Ref ID J:156146]

Johnson WB; Ruppe MD; Rockenstein EM; Price J; Sarthy VP; Verderber LC; Mucke L. 1995. Indicator expression directed by regulatory sequences of the glial fibrillary acidic protein (GFAP) gene: in vivo comparison of distinct GFAP-lacZ transgenes. Glia 13(3):174-84. [PubMed: 7782103]  [MGI Ref ID J:113204]

Liu B; Zupan B; Laird E; Klein S; Gleason G; Bozinoski M; Gal Toth J; Toth M. 2014. Maternal hematopoietic TNF, via milk chemokines, programs hippocampal development and memory. Nat Neurosci 17(1):97-105. [PubMed: 24292233]  [MGI Ref ID J:207927]

Savidge TC; Newman P; Pothoulakis C; Ruhl A; Neunlist M; Bourreille A; Hurst R; Sofroniew MV. 2007. Enteric glia regulate intestinal barrier function and inflammation via release of S-nitrosoglutathione. Gastroenterology 132(4):1344-58. [PubMed: 17408650]  [MGI Ref ID J:128327]

Saxe MD; Battaglia F; Wang JW; Malleret G; David DJ; Monckton JE; Garcia AD; Sofroniew MV; Kandel ER; Santarelli L; Hen R; Drew MR. 2006. Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate gyrus. Proc Natl Acad Sci U S A 103(46):17501-6. [PubMed: 17088541]  [MGI Ref ID J:117099]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & HusbandryWhen maintaining a live colony, these mice are maintained by breeding hemizygous females to wildtype as transgenic males are infertile.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2525.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Frozen Products

Price (US dollars $)
Frozen Embryo $1650.00

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryopreserved Embryos
    Available to most shipping destinations1
    This strain is also available as cryopreserved embryos2. Orders for cryopreserved embryos may be placed with our Customer Service Department. Experienced technicians at The Jackson Laboratory have recovered frozen embryos of this strain successfully. We will provide you enough embryos to perform two embryo transfers. The Jackson Laboratory does not guarantee successful recovery at your facility. For complete information on purchasing embryos, please visit our Cryopreserved Embryos web page.

    1 Shipments cannot be made to Australia due to Australian government import restrictions.
    2 Embryos for most strains are cryopreserved at the two cell stage while some strains are cryopreserved at the eight cell stage. If this information is important to you, please contact Customer Service.
  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3283.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Frozen Products

Price (US dollars $)
Frozen Embryo $2145.00

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryopreserved Embryos
    Available to most shipping destinations1
    This strain is also available as cryopreserved embryos2. Orders for cryopreserved embryos may be placed with our Customer Service Department. Experienced technicians at The Jackson Laboratory have recovered frozen embryos of this strain successfully. We will provide you enough embryos to perform two embryo transfers. The Jackson Laboratory does not guarantee successful recovery at your facility. For complete information on purchasing embryos, please visit our Cryopreserved Embryos web page.

    1 Shipments cannot be made to Australia due to Australian government import restrictions.
    2 Embryos for most strains are cryopreserved at the two cell stage while some strains are cryopreserved at the eight cell stage. If this information is important to you, please contact Customer Service.
  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Control Information

  Control
   Noncarrier
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)